GEMCITABINE HYDROCHLORIDE LY-188011 Gemzar BDBM50247964 Gemcitabine HCl CHEBI:31647
BDBM429521 med.21724, Compound Gemcitabine
AEE788 6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine BDBM26105
- Sayyad, N; Vrettos, EI; Karampelas, T; Chatzigiannis, CM; Spyridaki, K; Liapakis, G; Tamvakopoulos, C; Tzakos, AG Development of bioactive gemcitabine-D-Lys Eur J Med Chem 166: 256-266 (2019)
- Baraniak, J; Pietkiewicz, A; Kaczmarek, R; Radzikowska, E; Kulik, K; Krolewska, K; Cieslak, M; Krakowiak, A; Nawrot, B N-Acyl-phosphoramidates as potential novel form of gemcitabine prodrugs. Bioorg Med Chem 22: 2133-40 (2014)
- Jiang, Y; Hou, J; Li, X; Huang, Y; Wang, X; Wu, J; Zhang, J; Xu, W; Zhang, Y Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity. Bioorg Med Chem 24: 5787-5795 (2016)
- Chatzisideri, T; Leonidis, G; Karampelas, T; Skavatsou, E; Velentza-Almpani, A; Bianchini, F; Tamvakopoulos, C; Sarli, V Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of Gemcitabine. J Med Chem 65: 271-284 (2022)
- Correia, C; Xavier, CPR; Duarte, D; Ferreira, A; Moreira, S; Vasconcelos, MH; Vale, N Development of potent CPP6-gemcitabine conjugates against human prostate cancer cell line (PC-3). RSC Med Chem 11: 268-273 (2020)
- Li, Y; Liu, Y; Chen, Y; Wang, K; Luan, Y Design, synthesis and antitumor activity study of a gemcitabine prodrug conjugated with a HDAC6 inhibitor. Bioorg Med Chem Lett 72: (2022)
- Evo312: An Evodiamine Analog and Novel PKCĪ²I Inhibitor with Potent Antitumor Activity in Gemcitabine-Resistant Pancreatic Cancer.
- Kang, Z; Wang, C; Tong, Y; Li, Y; Gao, Y; Hou, S; Hao, M; Han, X; Wang, B; Wang, Q; Zhang, C Novel Nonsecosteroidal Vitamin D Receptor Modulator Combined with Gemcitabine Enhances Pancreatic Cancer Therapy through Remodeling of the Tumor Microenvironment. J Med Chem 64: 629-643 (2021)
- Vrettos, EI; Karampelas, T; Sayyad, N; Kougioumtzi, A; Syed, N; Crook, T; Murphy, C; Tamvakopoulos, C; Tzakos, AG Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancer. Eur J Med Chem 211: (2021)
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.